NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market,” please visit: https://nnw.fm/qBAbh
Artificial intelligence (AI) continues to transform healthcare innovation, with medical imaging emerging as one of its most promising frontiers. In breast cancer detection, where early identification often determines patient outcomes, AI-powered imaging technologies are pushing beyond the technical constraints of traditional mammography, tomosynthesis, and MRI. Globally, breast cancer remains the most frequently diagnosed cancer among women. The World Health Organization (WHO) reported that more than 2.3 million women were diagnosed, with approximately 670,000 losing their lives to the disease in 2022. In the United States, the American Cancer Society (ACS) estimates that 316,950 new invasive breast cancer cases will be identified this year alone.
This urgent demand for faster, more accurate diagnostic tools is driving a surge of innovation across the imaging sector. Within this fast-evolving field, Izotropic Corporation is distinguishing itself with the IzoView Breast CT Imaging System, a purpose-built 3D imaging solution engineered to enhance cancer detection accuracy, particularly in women with dense breast tissue.
About Izotropic Corporation
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) is a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses and treatment of breast cancers
More information about Izotropic can be found on its website at IzoCorp.com
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
This email address is being protected from spambots. You need JavaScript enabled to view it.
NetworkNewsWire is powered by IBN

| Last Trade: | C$0.34 |
| Daily Change: | 0.005 1.49 |
| Daily Volume: | 9,000 |
| Market Cap: | C$22.650M |
September 23, 2025 September 03, 2025 August 28, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load